Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

Corporate borrowers shrugged off fears over inflation and concerns over tariffs to print tight trades and pay for ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors. The therapy is a ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

About Scorpion Therapeutics Scorpion is a clinical-stage, precision oncology company developing transformational targeted therapies for patients with cancer. We have built proprietary and fully ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

Plymouth drugmaker IDRx was bought by GSK plc (NYSE: GSK) for $1 billion upfront, while Eli Lilly and Co. paid Boston-based Scorpion Therapeutics Inc. up to $2.5 billion for its lead cancer drug.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Glick, Ph.D., who has been with the firm since its inception in 2021 and was previously founder of IFM Therapeutics and Scorpion Therapeutics. Eli Lilly & Company announced its agreement to ...